Bristol Myers Squibb spells out OS benefit of Opdivo/Yervoy combo plus 'limited' chemotherapy — is it enough to change practice?
Normally when a PD-1 inhibitor is given with chemotherapy as a first-line treatment of non-small cell lung cancer — a regimen popularized by Merck and its market-leading checkpoint drug Keytruda — patients go through four cycles of chemo, sometimes more as maintenance. Bristol Myers Squibb set out to test in CHECKMATE-9LA whether two cycles plus a combination of Opdivo and Yervoy would do the job. At ASCO, they will be making the case that it does.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.